Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRadimedFRA:46K -0.59%91 Return-on-Tangible-Equity is 25.12% as of Mar. 2026, which is 32% above its 10-year median of 19.05. GuruFocus rates FRA:46K with a GF Score™ of 91/100 and a GF Value™ of €56.93 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 760 Medical Devices & Instruments companies, iRadimed ranks better than 87.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. iRadimed's annualized net income for the quarter that ended in Mar. 2026 was €20.13 Mil. iRadimed's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €80.14 Mil. Therefore, iRadimed's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 25.12%.
The historical rank and industry rank for iRadimed's Return-on-Tangible-Equity or its related term are showing as below:
FRA:46K'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.59 Med: 19.05 Max: 25.71
Current: 25.71
During the past 13 years, iRadimed's highest Return-on-Tangible-Equity was 25.71%. The lowest was 1.59%. And the median was 19.05%.
FRA:46K's Return-on-Tangible-Equity is ranked better than 87.24% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs FRA:46K: 25.71
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
iRadimed Return-on-Tangible-Equity Related Terms
iRadimed Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for iRadimed's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:46K vs AVNS, LMRI, AORT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, iRadimed's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRadimed Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where iRadimed's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 25.12% mean?
iRadimed (FRA:46K) has a Return-on-Tangible-Equity of 25.12% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on iRadimed and its competitors. This is 32% above median its historical median of 19.05. Over the past decade, iRadimed's Return-on-Tangible-Equity has ranged from 1.59 to 25.71. According to the industry distribution chart, iRadimed ranks #97 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is iRadimed's Return-on-Tangible-Equity too high?
iRadimed's current Return-on-Tangible-Equity of 25.12% is 32% above median its 10-year median of 19.05. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 25.71. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. iRadimed's value of 25.12% is 523.3% above this industry median. Based on the distribution chart, iRadimed ranks #97 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRadimed has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Return-on-Tangible-Equity compare to AVNS and LMRI?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #97 out of 760 companies for Return-on-Tangible-Equity. This places iRadimed in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. iRadimed's value of 25.12% is 523.3% above this benchmark. Historically, iRadimed's own Return-on-Tangible-Equity has ranged from 1.59 to 25.71 over the past decade. While the company's 10-year median is 19.05 vs. the industry median of 4.03, iRadimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRadimed's current Return-on-Tangible-Equity of 25.12% is 523.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on iRadimed and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRadimed's current Return-on-Tangible-Equity is 25.12%, which is 32% above median its own 10-year median of 19.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.93, compared to a current price of €84.00 — trading 47.5% above its estimated fair value. The current Return-on-Tangible-Equity is 25.12%, which is 32% above median its 10-year median of 19.05 and 523.3% above the Medical Devices & Instruments industry median of 4.03. iRadimed's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Return-on-Tangible-Equity is 25.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (FRA:46K) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of €84.00 is trading 47.5% above its estimated GF Value™ of €56.93.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for FRA:46K:
Return-on-Tangible-Equity: 25.12% (32% above median its 10-year median of 19.05)
GF Value™: €56.93 vs. price of €84.00 (47.5% above fair value)
Industry Position: 523.3% above the Medical Devices & Instruments median (#97 of 760)
No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
91GF Score
Get the complete analysis for FRA:46K
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:46K has been successfully added to your 
